You just read:

New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds

News provided by

Nektar Therapeutics

May 22, 2017, 09:00 ET